New therapeutic strategies for celiac disease

Autoimmunity Reviews

Volumn 9, Issue 3, 2010, Pages 144-147

  Lerner, Aaron ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

Celiac disease; Gluten; Immunomodulation; Propyl endopeptidase; Therapy; Tissue transglutaminase

Indexed keywords

ALPHA4 INTEGRIN; GAMMA INTERFERON; GLUTEN; INTEGRIN ALPHA 4 BETA7; INTERLEUKIN 15; MITOGENIC AGENT; PEPTIDE VACCINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; RECOMBINANT INTERLEUKIN 10; UNCLASSIFIED DRUG;

CELIAC DISEASE; DEAMINATION; DETOXIFICATION; ENVIRONMENTAL FACTOR; ENZYME DEGRADATION; GLUTEN FREE DIET; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; PALATABILITY; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; WHEAT;

ANIMALS; CELIAC DISEASE; DIET, GLUTEN-FREE; GLUTENS; HUMANS; IMMUNE TOLERANCE; VACCINATION;

EID: 72149093493     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.05.002     Document Type: Review

References (40)

1. Lerner A., Blank M., and Shoenfeld Y. Celiac disease and autoimmunity. Isr J Med Sci 32 (1996) 33-36
2. Reif S., and Lerner A. Tissue transglutaminase - the key player in celiac disease: a review. Autoimmun Rev 3 (2004) 40-45
3. Shamir R., Eliakim R., Lahat N., Sobel E., and Lerner A. ELISA assay of anti endomysial antibodies in the diagnosis of celiac disease: comparison with immunofluorescence assay of anti endomysial antibodies and tissue transglutaminase antibodies. Isr Med Assoc J 4 (2002) 594-596
4. Kwon J.H., and Farrell R.J. Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients. Paediatr Drugs 8 (2006) 375-388
5. Periolo N., and Chernavsky A.C. Coeliac disease. Autoimmun Rev 5 (2006) 202-208
6. Shaoul R., and Lerner A. Associated authoantibodies in celiac disease. Autoimmun Rev 6 (2007) 559-565
7. Sollid L.M., and Khosla C. Future therapeutic options for celiac disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 140-147
8. Rossi M., Maurano F., and Luongo D. Immunomodulatory strategies for celiac disease. Int Rev Immunol 24 (2005) 479-499
9. Schuppan D., and Junker Y. Turning swords into plowshares: transglutaminase to detoxify gluten. Gastroenterology 133 (2007) 1025-1028
10. Londei M., Maiuri L., and Quaratino S. A search for the holy grail: non-toxic gluten for celiac patients. Gastroenterology 129 (2005) 1111-1113
11. Ciacci C., Maiuri L., Caporaso N., Bucci C., Del Giudice L., Massardo D.R., et al. Celiac disease: in vitro and in vivo safety and palatability of wheat-free sorghum food products. Clin Nutr 26 (2007) 799-805
12. Spaenij-Dekking L., Kooy-Winkelaar Y., van Veelen P., Drijfhout J.W., Jonker H., Van Soest L., et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 129 (2005) 797-806
13. Molberg O., Uhlen A.K., Jensen T., Flaete N.S., Fleckenstein B., Arentz-Hansen H., et al. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology 128 (2005) 393-401
14. Vader L.W., Stepniak D.T., Bunnik E.M., Kooy Y.M., de Haan W., Drijfhout J.W., et al. Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 125 (2003) 1105-1113
15. M. Pinier, E.F. Verdu, M. Nasser-Eddine, C.S. David, A. Vezina, N. Rivard, et al. Polymeric Binders Suppress Gliadin-Induced Toxicity in the Intestinal Epithelium. Gastroenterology 2009;136:288-98.
16. Anderson R.P., van Heel D.A., Tye-Din J.A., Jewell D.P., and Hill A.V. Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease. Gut 55 (2006) 485-491
17. Silano M., Di Benedetto R., Trecca A., Arrabito G., Leonardi F., and De Vincenzi M. A decapeptide from durum wheat prevents celiac peripheral blood lymphocytes from activation by gliadin peptides. Pediatr Res 61 (2007) 67-71
18. Silano M., Leonardi F., Trecca A., Mancini E., Di Benedetto R., and De Vincenzi M. Prevention by a decapeptide from durum wheat of in vitro gliadin peptide-induced apoptosis in small-bowel mucosa from coeliac patients. Scand J Gastroenterol 42 (2007) 786-787
19. Di Cagno R., de Angelis M., Alfonsi G., de Vincenzi M., Silano M., Vincentini O., et al. Pasta made from durum wheat semolina fermented with selected lactobacilli as a tool for a potential decrease of the gluten intolerance. J Agric Food Chem 53 (2005) 4393-4402
20. Matysiak-Budnik T., Candalh C., Cellier C., Dugave C., Namane A., Vidal-Martinez T., et al. Limited efficiency of prolyl-endopeptidase in the detoxification of gliadin peptides in celiac disease. Gastroenterology 129 (2005) 786-796
21. De Angelis M., Rizzello C.G., Fasano A., Clemente M.G., De Simone C., Silano, et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim Biophys Acta 1762 (2006) 80-93
22. Gianfrani C., Siciliano R.A., Facchiano A.M., Camarca A., Mazzeo M.F., Costantini S., et al. Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology 133 (2007) 780-789
23. Gobbetti M., Giuseppe Rizzello C., Di Cagno R., and De Angelis M. Sourdough lactobacilli and celiac disease. Food Microbiol 24 (2007) 187-196
24. Di Cagno R., Rizzello C.G., De Angelis M., Cassone A., Giuliani G., Benedusi A., et al. Use of selected sourdough strains of Lactobacillus for removing gluten and enhancing the nutritional properties of gluten-free bread. J Food Prot 71 (2008) 1491-1495
25. Gass J., and Khosla C. Prolyl endopeptidases. Cell Mol Life Sci 64 (2007) 345-355
26. Pyle G.G., Paaso B., Anderson B.E., Allen D.D., Marti T., Li Q., et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol 3 (2005) 687-694
27. Di Cagno R., De Angelis M., Auricchio S., Greco L., Clarke C., De Vincenzi M., et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 70 (2004) 1088-1096
28. Gass J., Bethune M.T., Siegel M., and Spencer A. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133 (2007) 472-480
29. Paterson B.M., Lammers K.M., Arrieta M.C., Fasano A., and Meddings J.B. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 26 (2007) 757-766
30. Esposito C., Caputo I., and Troncone R. New therapeutic strategies for coeliac disease: tissue transglutaminase as a target. Curr Med Chem 14 (2007) 2572-2580
31. Choi K., Siegel M., Piper J.L., Yuan L., Cho E., Strnad P., et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 12 (2005) 469-475
32. Silano M., Vincentini O., Iapello A., Mancini E., and De Vincenzi M. Antagonist peptides of the gliadin T-cell stimulatory sequences: a therapeutic strategy for celiac disease. J Clin Gastroenterol 42 Suppl 3 Pt 2 (2008) S191-S192
33. Fraser J.S., Engel W., Ellis H.J., Moodie S.J., Pollock E.L., and Wieser H. Coeliac disease: in vivo toxicity of the putative immunodominant epitope. Gut 52 (2003) 1698-1702
34. Silano M., Di benedetto R., Maialetti F., De Vincenzi A., Calcaterra R., Trecca A., et al. A 10-residue peptide from durum wheat promotes a shift from a Th1-type response toward a Th2-type response in celiac disease. Am J Clin Nutr 87 (2008) 415-423
35. Salvati V.M., Mazzarella G., Gianfrani C., Levings M.K., Stefanile R., De Giulio B., et al. Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut 54 (2005) 46-53
36. Anderson R.P., Degano P., Godkin A.J., Jewell D.P., and Hill A.V. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 6 (2000) 337-342
37. Gianfrani C., Levings M.K., Sartirana C., Mazzarella G., Barba G., Zanzi D., et al. Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol 177 (2006) 4178-4186
38. Senger S., Luongo D., Maurano F., Mazzeo M.F., Siciliano R.A., Gianfrani C., et al. Intranasal administration of a recombinant alpha-gliadin down-regulates the immune response to wheat gliadin in DQ8 transgenic mice. Immunol Lett 88 (2003) 127-134
39. Zhao J., de Vera J., Narushima S., Beck E.X., Palencia S., Shinkawa P., et al. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. Gastroenterology 132 (2007) 1331-1343
40. Briani C., Samaroo D., and Alaedini A. Celiac disease: from gluten to autoimmunity. Autoimmun Rev 7 (2008) 644-650